The Heart Hive - Cardiomyopathy Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Research genetic analysis.
- Who it may be relevant to
- Registry conditions: Cardiomyopathies, Myocarditis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Longitudinal Observational Study of Self-reported Cardiomyopathy in the Heart Hive
Overview
This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies.
Detailed description
This study utilises The Heart Hive, an international, online registry of patients with self-reported clinically diagnosed cardiomyopathy or myocarditis, and people with a family history of cardiomyopathy, enrolled on an on-going basis. Registry participants are invited to enter self-reported demographics and health data relevant to their cardiac diagnosis into The Heart Hive online database.
Registry participants with self-reported clinically diagnosed cardiomyopathy will be recruited to an observational, prospective study entailing collection of patient-reported baseline demographic data and clinical risk factors, genotyping, and annual collection of follow up data from patients, national registries (NHS England) and medical records.
In the pilot phase 100 DCM and 100 HCM patients will be recruited to a validation study. Consent will be sought to access medical information from health care providers in order to compare against and confirm self-reported health information. DNA will be obtained from saliva samples and tested in-house using a panel of clinically validated known Mendelian DCM and HCM genes as a second validation of the accuracy of self-reported diagnosis and to confirm equivalent genetic architecture of DCM and HCM in direct-to-patient recruited cohorts compared to traditional centre of excellence clinic-based recruitments.
Following validation of the approach and once funding is in place for genomic studies, larger numbers of cardiomyopathy patients will be recruited to this study from the registry of research willing participants.
Interventions
- Genetic Research genetic analysis
Genetic analysis of DNA extracted from saliva. Participants can opt in to receive individual results of research genetic analysis for a predefined panel of clinically actionable cardiomyopathy genes.
Primary outcome measures
- Number of participants with cardiovascular cause of death [Time frame: 90 years]
- Number of participants with arrhythmic events [Time frame: 90 years]
- Number of participants with major heart failure events [Time frame: 90 years]
Eligibility criteria
Inclusion criteria
- Adult (age 18 and over),
- Males and Females,
- Capacity to provide informed consent,
- Patients with a confirmed diagnosis of cardiomyopathy or myocarditis,
- People with a family history of cardiomyopathy confirmed in a first or second degree relative.
Note: Pregnant women are eligible. This study is observational and entirely separate from clinical care.
Exclusion criteria
- Patients who lack capacity to consent for themselves,
- Vulnerable groups (e.g. those under 18, prisoners, those in a dependent relationship, the mentally ill).
- Patients with a confirmed history of coronary artery disease:
- who have been informed by their treating physician that their cardiomyopathy is secondary to their coronary artery disease, or
- who have undergone previous percutaneous coronary intervention or coronary bypass surgery
- History of primary valvular heart disease or congenital heart disease
- Severe, untreated or untreatable hypertension (systolic blood pressures routinely >180 mm Hg and/or diastolic blood pressures >120 mm Hg)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United Kingdom · 1 center
- Imperial College London — London
Identifiers
NCT: NCT04612296 · 18IC4954